[Discrepancy between clinical data and approval documents]

Fritz Mellert1, Jan-Malte Sinning2

  • 1Klinik und Poliklinik für Herzchirurgie, Universitätsklinikum Bonn.

Insights

Pacemakers, implantable cardioverter-defibrillators (ICDs), and stents are vital cardiac devices. A new study reveals discrepancies between FDA registration data and published research on these high-risk cardiovascular products.

Area of Science:

  • Cardiology
  • Medical Device Regulation
  • Clinical Research

Background:

  • Pacemakers, implantable cardioverter-defibrillators (ICDs), and stents are critical cardiovascular implantable electronic devices (CIEDs).
  • Concerns exist regarding device malfunctions and associated patient mortality.
  • Regulatory bodies like the US Food and Drug Administration (FDA) oversee these high-risk medical products.

Purpose of the Study:

  • To compare the study findings reported in FDA registration documents for cardiac high-risk products with those in peer-reviewed scientific publications.
  • To assess potential discrepancies in reported outcomes and safety data between regulatory submissions and published literature.

Main Methods:

  • A comparative analysis was conducted on data submitted to the FDA for cardiac high-risk devices.
  • Study results from these regulatory documents were contrasted with findings from peer-reviewed publications on the same devices.
  • The research focused on identifying differences in reported malfunctions and mortality rates.

Main Results:

  • Preliminary analysis indicates potential variations in the reporting of device performance and safety.
  • Discrepancies may exist in the characterization of malfunctions and adverse events between FDA filings and published studies.
  • Further investigation is needed to quantify the extent and implications of these differences.

Conclusions:

  • The comparison highlights the importance of scrutinizing data from both regulatory and published sources for a comprehensive understanding of device safety.
  • Ensuring consistency in reporting across different platforms is crucial for accurate risk assessment and patient safety in cardiology.
  • This study underscores the need for transparency and alignment in medical device research reporting.

Related Concept Videos

Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
283
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
329
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
393
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
243